Citations should be made in the following way: Authors. Title. Eur Respir J 2016; 48: Suppl. 60, abstract number.
Citations should be made in the following way: Authors. Title. Eur Respir J 2016; 48: Suppl. 60, abstract number.
Do we really need PD1/PD-L1 status and next generation sequencing to treat lung cancer?
Lunchtime sessionChairs: Joanna Chorostowska-Wynimko (Warszawa, Poland), Thomas Wehler (Homburg/Saar, Germany)
Aims: Today, immunooncology has almost completely revolutionised the treatment of various cancer types, especially lung cancer. Moreover, encouraging preliminary data are available for mesothelioma. These entities respond to PD-1 and PD-L1 inhibition. In addition, more and more targeted agents for lung cancer therapy are becoming available: these agents go beyond the tyrosine kinase blockade of mutated EGFR and rearranged ALK. Another marked advance is Next Generation Sequencing (NGS), which facilitates the detection of many dozens of mutations at the same time. However, the provocative question from the clinical standpoint remains: is detailed molecular testing essential for treating patients with these drugs?